What does this research mean for the field?

First-line comprehensive genomic profiling (CGP) to guide molecularly-matched therapy significantly improves overall survival and access to targeted treatments in patients with advanced solid tumors compared to standard of care. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

To assess the effects of first-line comprehensive genomic profiling on survival among patients with advanced solid tumors receiving molecularly-matched therapies.

May 29, 2026Journal of Clinical Oncology

Impact of first-line comprehensive genomic profiling on survival outcomes for patients with advanced solid tumors who received molecularly-matched therapies: 3-year follow-up of the prospective FIRST-Dx study.

View Full Paper

Ask AI

Bookmark

To assess the effects of first-line comprehensive genomic profiling on survival among patients with advanced solid tumors receiving molecularly-matched therapies.
Multi-institutional prospective study in Japan involving 172 chemotherapy-naïve adults with advanced solid tumors.
3-year follow-up focused on overall survival as primary endpoint and secondary outcomes such as progression-free survival and response rates.
Exploratory analysis compared patients from study with real-world patients using propensity score matching.
Median overall survival significantly longer in patients treated with molecularly-matched therapies (not reached) compared to standard of care (26.2 months, HR 0.62 [95% CI: 0.39–0.99], p=0.047).
Among second-line MBRT patients, the median PFS ratio was 1.2, with 47% showing meaningful clinical benefit.
FIRST-Dx patients had median overall survival of 23.5 months versus 13.4 months in the real-world group (HR 0.61 [95% CI: 0.40–0.94], p=0.02).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial evaluates survival outcomes in advanced solid tumors, indicating CGP improves access to targeted therapies.

Cite This Study

Ikeda et al. (2026) studied this question.

synapsesocial.com/papers/6a192eb9fab5b468c4417ee8 https://doi.org/10.1200/jco.2026.44.16_suppl.3134

View Full Paper

Ask AI

Bookmark

Impact of first-line comprehensive genomic profiling on survival outcomes for patients with advanced solid tumors who received molecularly-matched therapies: 3-year follow-up of the prospective FIRST-Dx study.

Key Points

Discussion

Implication

Cite This Study

Impact of first-line comprehensive genomic profiling on survival outcomes for patients with advanced solid tumors who received molecularly-matched therapies: 3-year follow-up of the prospective FIRST-Dx study.

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider